News-Medical.Net November 12, 2024
New review highlights how mini-organs model tumor environments, enhance drug testing, and pave the way for personalized cancer treatments.
Study: Patient-derived organoids in precision cancer medicine. Image Credit: RaffMaster/Shutterstock.com
In a recent review published in Med, researchers explored the use of patient-derived organoids (PDOs), or lab-grown mini-organs, as powerful tools in cancer research. PDOs replicate the complexity of human tumors, allowing for advanced studies of the tumor microenvironment (TME) and serving as preclinical models for gene editing, molecular profiling, drug testing, and biomarker discovery—crucial for personalized treatment approaches.
Background
Organoids are 3D models derived from patient cells that offer an accurate representation of human tissue. Recently approved as alternative drug-testing methods, organoids hold potential to replace animal models, providing insights...
Today's Sponsors
Today's Sponsor